NCT01191840已完成2 期
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 509
- 试验地点
- 15
- 主要终点
- Cure Rate
研究概览
简要总结
The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.
详细描述
To demonstrate that the clinical efficacy of algorithm-based therapy of patients with staphylococcal blood stream infection is noninferior to current standard of care.
PP (per protocol) population: randomized patients EXCLUDING those that: Received a PENS antibiotic -Did not undergo removal of intravascular catheter suspected to be infected. Note that patients with simple CoNS bacteremia may retain the catheter; all other patients should have their catheter(s) removed. -Had blood stream infection with a vancomycin-resistant staphylococcus; or a staphylococcus resistant to protocol-identified alternative drugs if these were used -Discontinued study medication prematurely for reasons other than clinical failure -Did not undergo final TOC assessment -Did not comply with all Patient Inclusion Criteria -Violated any Patient Exclusion Criteria
- Died within 3 days of randomization
- Were classified as non-evaluable
PPE Population: Patients from the PP population who did not have complicated staphylococcal infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide signed and dated informed consent. The patient's legally authorized representative (LAR) can provide a signed informed consent for the patient if allowed by local Institutional Review Board/Ethics Committee (IRB/EC) policy.
- •Is ≥ 18 yrs of age.
- •If the subject has an intravenous catheter in place then the subject and his/her primary health care provider must agree to have the catheter removed within 5 days of the initial blood culture draw with the exception of those subjects who meet criteria for simple CoNS bacteremia as defined in Table
- •The catheter may be retained in those subjects with simple CoNS bacteremia.
- •Has blood stream infection defined as at least one blood culture positive for S. aureus or CoNS. In most cases, vancomycin(or other study drug alternative) will have been started prior to randomization. Enrollment windows depend on speciation and clinical classification as follows:
- •identification of CoNS and classification as simple per Table 1-must be randomized within 3 calendar days of the start of treatment effective for the baseline infecting pathogen
- •identification of CoNS and classification as uncomplicated per Table 1 must be randomized within 4 calendar days of the start of treatment effective for the baseline infecting pathogen
- •identification of S. aureus - must be randomized within 12 calendar days of the start of treatment effective for the baseline infecting pathogen
- •This criterion has been removed
- •Women of child bearing potential must have a negative urine and/or serum pregnancy test.
- •All patients of reproductive potential must be abstinent or agree to use double-barrier contraception while receiving study (algorithm based or Standard of Care) therapy.
排除标准
- •Has known or suspected new complicated staphylococcal infection at the time of enrollment.
- •Weigh ≥ 200 kg.
- •Has non-removable intravascular foreign material at the time a positive blood culture was drawn (e.g., intracardiac pacemaker or cardioverter/defibrillator wires, hemodialysis access grafts, cardiac prosthetic valve, valvular support ring). Exception: coronary stents, inferior vena cava (IVC) filters in place > 6 weeks, patients with pacemakers whose baseline infecting pathogen is a CoNS, vascular stents in place for > 6 weeks, non-hemodialysis grafts in place >90 days and hemodialysis grafts not used within past 12 months and not previously infected are eligible for randomization. Arthroplasties and other extravascular devices, e.g. synthetic hernia repair mesh, and non-arthroplasty orthopedic prostheses including pins or plates, are acceptable as long as there are no signs or symptoms of foreign material-related infection at the time of randomization.
- •This criterion has been removed
- •Has a moribund clinical condition such that there is a high likelihood of death or cardiac surgery during the next three days.
- •Has shock or hypotension (supine systolic blood pressure < 80 mmHg) or oliguria (urine output < 20 mL/h) unresponsive to fluids or pressors within four hours.
- •Has received an investigational antibacterial agent with anti-staphylococcal activity within 30 days prior to randomization.
- •Has a documented history of significant allergy or intolerance to all protocol-approved antibiotics anticipated to be effective for their infection.
- •Has an infecting pathogen with confirmed reduced susceptibility to vancomycin (Minimum Inhibitory Concentrations (MIC) > 2 µg/mL) if known. Note: If reduced susceptibility to vancomycin is discovered after enrollment, the patient will be treated with daptomycin (if pathogen is susceptible). Patient will remain in study as appropriate and be evaluated in the Intent to Treat (ITT) analysis, but will be excluded from Protocol Population (PP) analyses.
- •For S. Aureus patients, is severely neutropenic (absolute neutrophil count < 0.100x103/mm3) or is anticipated to develop severe neutropenia (absolute neutrophil count < 0.100x103/ mm3) during the study treatment period due to prior or planned chemotherapy. CoNS patients with neutropenia are eligible to be enrolled.
- •This criterion has been removed
- •Has previously known Human Immunodeficiency Virus (HIV) infection with a nadir CD4+ count of <100 cells/mm3 within the past 12 months
- •Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations.
- •Is pregnant or trying to get pregnant, nursing, or lactating.
- •Has known or suspected septic arthritis, osteomyelitis, pneumonia or other metastatic focus of infection. CoNS patients with pneumonia and not being treated or anticipated to start treatment with antibiotics effective for the baseline infecting pathogen can be included
- •Has polymicrobial blood stream infection including at least one non-staphylococcal species, except AFTER consultation with the Clinical Medical Monitor at DCRI. Note that it is possible that a subject may not have a known polymicrobial bloodstream infection at the time of randomization, but additional pathogen(s) can subsequently be isolated from the initial blood culture. These patients will be eligible to remain in the trial. Please also note that patients with S. aureus plus CoNS will follow the treatment pathway for S. aureus.
- •This criterion has been removed.
- •Is hemodialysis dependent or has end stage renal disease (Creatinine Clearance (CrCl) < 30 cc/min).
- •Developed Staphylococcus aureus blood stream infection within 72 hours of percutaneous coronary revascularization
- •Received of any of the following antibiotics for 7 or more of the 10 calendar days immediately preceding the calendar day that the initial positive blood culture was drawn:
- •If methicillin susceptibility of the isolate is unknown at the time of enrollment: vancomycin; daptomycin; telavancin; tigecycline; linezolid (in either oral or IV administration); quinupristin/dalfopristin; piperacillin/tazobactam; penicillin; nafcillin; oxacillin; cloxacillin; cefazolin, ceftriaxone, ceftaroline, dalbavancin, oritavancin, tedizolid, and levofloxacin or equivalent fluoroquinolone (in either oral or IV administration) Note: ciprofloxacin is not an exclusion criteria.
- •If the staphylococcal isolate is known to be methicillin resistant: vancomycin; daptomycin; telavancin; tigecycline; linezolid (in either oral or IV administration), quinupristin/dalfopristin, dalbavancin, oritavancin, tedizolid, and ceftaroline.
- •Note: patients who have developed bacteremia after at least 7 days of prophylaxis with oral antibiotics have by definition failed prophylaxis and the oral antibiotic can be deemed non-effective for the index bacteremia. Oral antibiotics that have failed as prophylaxis in this manner will not be considered exclusionary or count towards the number of antibiotic days but must be stopped upon randomization
- •Has previously participated in this study.
研究组 & 干预措施
Algorithm-determined therapy
Experimental
干预措施: Vancomycin (Drug)
Standard of Care
Active Comparator
干预措施: Vancomycin (Drug)
结局指标
主要结局
Cure Rate
时间窗: Test of cure 2 (up to approximately 42 days)
To compare the cure rate at Test of Cure evaluation, between the proposed treatment algorithm and the standard of care therapy.
Number of Participants With Serious Adverse Events
时间窗: Test of cure 2 (up to approximately 42 days)
Number of Participants that reported a Serious Adverse Event
Number of Participants That Changed From Vancomycin to Another Study Antibiotic Due to an Adverse Event
时间窗: Test of cure 2 (up to approximately 42 days)
Patient changes from vancomycin or a protocol-approved study antibiotic to another protocol-approved study antibiotic due to AE associated with study drug
Number of Participants With Adverse Events Leading to Study Drug Withdrawal
时间窗: Test of cure 2 (up to approximately 42 days)
Number of Participants with an Adverse Event leading to study drug withdrawal
次要结局
- Antibiotic Days by Treatment Group(Test of cure 2 (up to approximately 42 days))
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary HypertensionHypertension, PulmonaryNCT00414687Bayer63
终止
不适用
Localized Alveolar Ridge Augmentation With Dental ImplantAlveolar Bone LossNCT00991965Medtronic Spinal and Biologics8
终止
不适用
Sinus Augmentation With Dental ImplantMaxillary Sinus Bone LossNCT00991393Medtronic Spinal and Biologics23
终止
3 期
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019Relapsing-Remitting Multiple SclerosisMultiple SclerosisNCT01797965Biogen1,501
已完成
3 期
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without CirrhosisHepatitis C Virus InfectionNCT02114177Janssen Infectious Diseases BVBA310